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Acute exacerbations are an important feature of chronic
obstructive pulmonary disease (COPD), with long-term implica-
tions for patients and the health system. Physiotherapists play an
integral role in the treatment of people with exacerbations of
COPD, with high-level evidence that physiotherapy interventions
can aid recovery and prevent recurrence. This review summarises
the respiratory and systemic consequences of an acute exacerba-
tion of COPD (AECOPD); the burden of exacerbations for
individuals and the health system; management of AECOPD, with
a focus on important physiotherapy interventions; prevention of
AECOPD; and future directions for research and practice.
What is an acute exacerbation of COPD?
The Global Initiative for Obstructive Lung Disease (GOLD)
strategy deﬁnes an exacerbation of COPD as ‘an acute event
characterised by a worsening of the patient’s respiratory symptoms
that is beyond normal day-to-day variations and leads to a change in
medication’.1 People with COPD experience between one and four
exacerbations per year.2 Important symptoms include dyspnoea (in
84% of individuals), fatigue (81%), runny nose (59%), changes in
sputumcolour (53%)oramount (47%), andcough (44%).3As there are
no biomarkers that can reliably detect a COPD exacerbation, the
diagnosisdependsonpatient reportandclinicalpresentation.Whilst
the GOLD deﬁnition suggests that a diagnosis of AECOPD requires a
change inmedicalmanagement, up to 40% of exacerbationsmay not
be reported to health professionals and these untreated exacerba-
tions may have a signiﬁcant impact on health status.4
The most common cause of a COPD exacerbation is thought to
be viral infection, most often rhinovirus.5 Exacerbations with
documented viral infection are associated with more severe
symptoms and slower recovery than thosewithout viral infection.5
Bacterial infection is a less common cause of exacerbation.
However, as many COPD airways are colonised with bacteria,
secondary bacterial infection occurs in up to 60% of cases.6
Exacerbations have also been attributed to environmentalhttp://dx.doi.org/10.1016/j.jphys.2014.08.018
1836-9553/ 2014 Australian Physiotherapy Association. Published by Elsevier B
creativecommons.org/licenses/by-nc-nd/3.0/).pollution. In one-third of severe exacerbations the cause may be
unknown.1 Exacerbations cluster in time7 and the strongest
predictor of future exacerbations is a history of exacerbations.8
During an acute exacerbation, exposure to a viral, bacterial or
environmental trigger causes worsening airway inﬂammation,
which exacerbates the chronic airway inﬂammation that is
characteristic of stable COPD. Increased inﬂammation and oxida-
tive stress in the COPD airway are manifested by increased airway
oedema and mucus hypersecretion, with worsening airway
obstruction, dynamic hyperinﬂation, dyspnoea and cough.9 Work
of breathing may be increased and in severe cases type-II
respiratory failure may occur. The inﬂammatory cascade that
occurs during an acute exacerbation is thought to contribute to
structural lung damage (eg, alveolarwall thickening, loss of surface
area for gas exchange) that is responsible for the progression of
COPD over time.
The adverse impact of an exacerbation may not be conﬁned to
the lungs. Systemic effects of AECOPD are well documented, with
increased levels of circulating pro-inﬂammatorymediators such as
ﬁbrinogen and interleukin-6.10 These systemic effects may
contribute to an increased risk of cardiovascular events, with a
2.27-fold increase in the risk of myocardial infarction during the
ﬁrst ﬁve days and a 1.26-fold increase in the risk of stroke during
the ﬁrst 49 days after an exacerbation.11 Peripheral muscle may
also be affected. During and after an exacerbation, people with
COPD demonstrate a decrease in quadriceps force that worsens
over the course of hospital admission.12,13 The causes of reduced
peripheral muscle force are not fully understood but are thought to
include corticosteroid treatment,14 systemic inﬂammation12 and
low levels of physical activity.15 People with COPD are highly
inactive during hospitalisation, with total walking duration as low
as 7 minutes per day.16
Burden of acute exacerbations of COPD
Acute exacerbations are critical events in the natural history of
COPD. They are associated with a more rapid decline in lung
function,17 a sustained reduction in health-related quality of life2.V. This is an open access article under the CC BY-NC-ND license (http://
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Figure 1. Interventions for management of acute exacerbations of chronic
obstructive pulmonary disease with associated levels of evidence.
ICU = intensive care unit, RCT = randomised controlled trial.
Holland: Physiotherapy management of COPD exacerbations182and increased risk of future exacerbations.7 Approximately 25% of
the decline in lung function in COPD is attributed to acute
exacerbations,17 which become more frequent as disease pro-
gresses.18 An exacerbation that is severe enough to require
hospitalisation is an independent predictor of all-cause mortality,
with death rates of 22 to 43% at 1 year following admission.19
People with COPD who have frequent exacerbations are
particularly at risk of adverse outcomes. Those who experienced
two or three exacerbations per year had faster declines in
respiratory function, fat free mass, physical activity and quality
of life than those with fewer exacerbations.2,8,20,21 The ‘frequent
exacerbator’ phenotype is consistent over time, such that those
patients who are observed to have frequent exacerbations are
likely to continue to have frequent exacerbations in the future.8
These patients are at high risk for adverse outcomes, regardless of
the severity of their underlying airﬂow limitation, and an
aggressive approach to therapy is recommended.1
The effects of acute exacerbations on muscle strength and
physical activity may have important long-term consequences.
Previous research has found that walking time in daily life does not
spontaneously recover at 1 month following hospital admission,
with minimal improvements seen in those who have the largest
decline in quadriceps strength.13 Following an exacerbation, low
levels of physical activity are associated with a 50% increase in the
risk of hospital readmission22 and a longer length of stay in
hospital for all subsequent admissions.13 In people with COPD,
physical inactivity is a stronger predictor of all cause mortality
than respiratory function, exercise capacity or nutritional status,
with an absolute 4-yearmortality risk of 31% in inactive patients.23
Exacerbations of COPD also have important consequences for
health systems and societies. Nearly 60% of the global cost of COPD
is associated with managing exacerbations, with the majority of
the ﬁnancial burden being associated with hospital treatment.24
This equates to costs in excess of A$550 million each year in
Australia,25 over £800million in the United Kingdom26 and US$4.5
billion in the United States of America.27 One percent of all
hospitalisations in Australia in the 2007–2008 ﬁnancial year were
for a primary diagnosis of COPD and the average length of stay was
twice as long as the overall average length of stay for any condition,
at 6.9 days compared to 3.3 days.25 In the USA, it is estimated that
20% of patients with COPD are readmitted within 30 days of
discharge, with an increase in costs of 30% for subsequent
admissions.27 General practice costs in the UK are doubled for
patients who experience two exacerbations per year compared to
those who experience none.28 In the light of the costs of COPD
exacerbations to individuals and the health system, there is a clear
imperative to provide optimal, evidence-based management.
Management of exacerbations of COPD
A summary of interventions used in the management of
AECOPD, along with the level of evidence that underpins their use,
is provided in Figure 1.
Pharmacological management
Short-acting inhaled beta-2 agonists are frequently prescribed
during an acute exacerbation of COPD, as consensus indicates that
they are of beneﬁt.1 These are equally effective when administered
via metered dose inhaler (with or without a spacer) compared to a
nebuliser.1 Systemic corticosteroids are a mainstay of treatment. A
systematic review including over 1000 patients found that
corticosteroids halved the risk of return to hospital within 30 days
(Peto OR 0.50, 95% CI 0.36 to 0.69).29 Those treated with
corticosteroids also had a shorter hospital stay (MD 1.22 days,
95% CI 0.18 to 2.26) and recovered their lung function more
quickly. However, adverse events were more common in those
treated with corticosteroids (Peto OR 2.33, 95% CI 1.60 to 3.40),
particularly hypoglycaemia.29 Antibiotics provide a clear survivalbeneﬁt for patients with a COPD exacerbation who are admitted to
intensive care (Peto OR 0.21, 95% CI 0.06 to 0.72). Antibiotics also
reduce length of hospital stay in this group with severe
exacerbations (mean reduction 9.6 days).30 However, the effects
of antibiotics in mild and moderate exacerbations are less clear,
with no mortality beneﬁt and inconsistent effects across different
outcomes. The GOLD standards suggest that antibiotics should be
prescribed to patients who have all three cardinal signs of an
exacerbation (increased dyspnoea, sputum volume, and sputum
purulence), or to patients with two of the cardinal signs, if one of
them is sputum purulence.1 Other pharmacological agents may be
required for treatment of comorbidities, including diuretics and
anticoagulants.
Controlled oxygen therapy
Oxygen therapy is important to prevent severe hypoxaemia
during exacerbations of COPD, but high levels of supplemental
oxygen may contribute to hypercapnia, acidosis and death.31
Oxygen therapy should be titrated to achieve oxyhaemoglobin
saturation (SpO2) between 88 and 92%,
31 and is usually adminis-
tered via nasal prongs or a venturi mask. Oxygen can also be
delivered using high ﬂow nasal cannulae, which may better meet
the inspiratory ﬂow demands of severely dyspnoeic patients and is
more tolerable than a face mask. Such systems can also provide
humidiﬁcation, which may be important to prevent sputum
retention in patients with excess secretions; however, there is no
evidence to guide practice in this area.
Non-invasive ventilation
Non-invasive ventilation is highly effective as a supportive
therapy for people with AECOPD complicated by type-II respirato-
ry failure. It unloads the respiratory muscles, restores acid-base
balance and provides time for pharmaceutical therapies to be
effective. A systematic review and meta-analysis showed that in
patients with COPD and acute hypercapnic respiratory failure
(PaCO2 > 45 mmHg, pH < 7.35), non-invasive ventilation reduced
mortality compared to usual care (RR 0.52, 95% CI 0.36 to 0.76) and
reduced the need for intubation (RR 0.41, 95% CI 0.33 to 0.53).32
There are also beneﬁts for the health system, with reduced length
of stay in those treated with non-invasive ventilation (MD –
3.24 days, 95% CI –4.41 to –2.06).32
Physiotherapists are frequently involved in the delivery of non-
invasive ventilation, including assessment and referral of appro-
priate patients, establishing patients on treatment, titration of
pressures, optimising patient tolerance and monitoring treatment
effects.33 Non-invasive ventilation may assist in delivery of other
physiotherapy treatments such as early mobilisation. In a group of
hospitalised patients who were recovering from acute-on-chronic
respiratory failure, most of whom had COPD, the use of non-
invasive ventilation and oxygen during walking resulted in
clinically signiﬁcant improvements in walking distance, oxyhae-
moglobin saturation and exercise-induced dyspnoea compared to
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Figure 2. Effect of airway clearance techniques on need for ventilatory assistance
during acute exacerbation of chronic obstructive pulmonary disease. Data are odds
ratios. No signiﬁcant difference in the odds of requiring ventilatory assistance
between those who did and did not receive airway clearance techniques.
ACTs = airway clearance techniques.
Invited Topical Review 183walking on oxygen alone.34 Non-invasive ventilation also im-
proved endurance time for unsupported upper limb exercise.
These results were obtained from patients who were as early as
2 days into their hospital admission, using inspiratory positive
airway pressure ranging from 15 to 18 cmH2O and expiratory
positive airway pressure ranging from 4 to 5 cmH2O.
Breathing exercises
Physiotherapists frequently use breathing exercises to relieve
dyspnoea, improve thoraco-abdominal co-ordination and enhance
functional capacity in people with acute exacerbations of COPD.
Commonly used techniques include breathing control (also known
as diaphragmatic or abdominal breathing) and pursed lip
breathing (gentle exhalation through lips that are pressed
together). Despite their widespread use in clinical practice,
evidence for important beneﬁts of breathing exercises in AECOPD
is scarce. A Cochrane review including 16 studies and 1233 parti-
cipants with stable COPD found that breathing exercises (pursed
lip breathing, pranayama yoga or diaphragmatic breathing)
improved functional exercise capacity when compared to no
treatment.35 Whether these ﬁndings are also applicable during
acute exacerbations is unclear. Recent randomised controlled trials
provide some evidence that breathing exercises may provide
symptomatic relief in patients who are hospitalised with acute
exacerbations of COPD. Patients who undertook twice daily
sessions of controlled breathing supervised by a physiotherapist,
consisting of relaxation exercises, pursed lip breathing and active
expiration, had greater improvements in anxiety, depression and
dyspnoea than those who undertook usual care.36 Similarly,
respiratory exercises during a hospital admission for AECOPD
(diaphragmatic breathing and pursed lip breathing) resulted in
lower levels of fatigue compared to usual care.37 It is not clear
whether ‘usual care’ in either study included other physiotherapy
interventions that are considered to be standard practice in many
settings, such as airway clearance techniques, mobilisation or
exercise training. Outcomes beyond the hospital admission were
not studied. However, these small trials provide preliminary
evidence that breathing techniques may be useful to aid symptom
control in the setting of AECOPD.
Whilst selected breathing techniques such as pursed lip
breathing may prove useful to manage symptoms during an
AECOPD, this does not extend to breathing techniques that aim to
improve lung volume, such as deep breathing exercises. During an
AECOPD, where the primary impairments are airﬂow obstruction,
expiratory ﬂow limitation and hyperinﬂation, augmentation of
lung volume may have adverse effects. Studies in COPD have
shown that although deep breathing exercises may increase
ventilation and improve blood gases, this is accompanied by
increased inspiratory muscle effort, reduced mechanical efﬁciency
of breathing and increased dyspnoea.38,39 As a result, deep
breathing exercises do not have a role in physiotherapy manage-
ment of AECOPD.
Airway clearance techniques
Increased cough, sputumvolume and sputumpurulence are key
features of AECOPD. Airway clearance techniques involve applica-
tion of physical forces to enhance removal of sputum from the
airway.40 Commonly used airway clearance techniques are the
forced expiration technique (FET, also known as hufﬁng), manual
chest physiotherapy and positive pressure devices. Assumptions
underlying the use of airway clearance techniques are that
retained sputum contributes to mucosal injury and airﬂow
obstruction, with longer-term impacts on re-exacerbation, hospi-
talisation and mortality.41 A recent Australian study found that
65% of cardiorespiratory physiotherapists frequently prescribe
airway clearance techniques for patients hospitalised with
AECOPD.42 This practice was supported by a Cochrane review
showing that in people with AECOPD, airway clearance techniquesreduced the need for ventilatory assistance (OR 0.21, 95% CI 0.05 to
0.85), reduced the duration of ventilatory assistance (MD –2.0
days, 95% CI –1.5 to –2.6) and reduced overall hospital length of
stay (MD –0.75 days, 95% CI –0.1 to –1.4).43 These results were
heavily inﬂuenced by trials using positive pressure techniques,
which generally hadmore favourable outcomes than those that did
not use positive pressure.
In addition to the Cochrane review,44 there are two large trials
of airway clearance techniques for AECOPD that have implications
for practice. A randomised controlled equivalence trial in
526 people hospitalised with an AECOPD found no difference in
quality of life at 6 months between those who received manual
chest physiotherapy (active cycle of breathing technique including
FET, percussion and vibration) and those who received only advice
about positioning and active cycle of breathing technique.44 There
was no difference in hospital length of stay between groups. The
trial had broad inclusion criteria and participants did not have to
be productive of sputum to take part. The results of this study
provide conﬁdence that manual chest physiotherapy techniques
do not have a routine role for people with AECOPD. Another
randomised trial comparing positive expiratory pressure therapy
(PEP) and FET to usual physiotherapy care in 90 people hospitalised
with AECOPD found no difference between groups in the primary
outcome – the Breathlessness, Cough and Sputum Scale – at any
time point during the 6-month followup.45 Although dyspnoea
improved more rapidly in the PEP group in the ﬁrst 8 weeks, by
6 months there were no clinically relevant or statistically
signiﬁcant differences between groups.When this trial is combined
with previous airway clearance technique studies in a meta-
analysis, the body of evidence no longer suggests an overall beneﬁt
of the techniques during AECOPD in the need for ventilatory
assistance (Figure 2; for a more detailed forest plot, see Figure 3 on
the eAddenda).45–49 The differing results between this trial and
previous studies may be related to the population studied, which
included fewer people who needed ventilatory assistance, or to the
more active comparison group, where usual physiotherapy care
included early mobilisation.49
In summary, current evidence for the effects of airway clearance
techniques in AECOPD is inconsistent across trials, but does not
suggest an overall beneﬁt of airway clearance techniques for
hospitalised patients. Whilst positive outcomes have been
reported in the sickest patients (ie, those requiring or at risk of
requiring invasive or non-invasive ventilatory assistance) in the
most recent Cochrane review,43 these effects are small and are not
supported by the results of a recent large trial.49 There is no
evidence thatmanual chest physiotherapy techniques are useful in
AECOPD. However, it should be recognised that many studies do
not account for different COPD phenotypes (eg, those who are
copious or regular sputum producers, or who have underlying
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Figure 4. Effect of early rehabilitation during acute exacerbations of chronic
obstructive pulmonary disease on mortality. Data are odds ratios. Odds of death
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Figure 6. Effect of early rehabilitation during acute exacerbations of chronic
obstructive pulmonary disease on hospital readmission during follow-up. Data are
odds ratios. Odds of hospital readmission did not differ between those commencing
rehabilitation during hospital admission compared to usual care, but decreased in
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Holland: Physiotherapy management of COPD exacerbations184bronchiectasis41). Whilst attempts to identify ‘responders’ to
airway clearance techniques in AECOPD have not been successful
to date,49 this does not exclude a role for the techinques in carefully
selected patients inwhomexcessive sputumproduction or sputum
retention are clinically important problems.
Early mobilisation and early rehabilitation
Early mobilisation, which aims to prevent functional decline
and facilitate hospital discharge, is a key element of physiotherapy
management for AECOPD. This includes early ambulation,
commenced within 24 hours of hospital admission, and may also
include targeted strength training and goal-directed practice (eg,
stair training) to achieve a safe discharge back to the community.
There is some evidence to support the efﬁcacy of this low-intensity
exercise training as part of a broader package of care. A Cochrane
review examined the impact of multidisciplinary interventions
including exercise programs to improve strength or function in
acute medical inpatients aged 65 years or older.50 Of nine included
trials, seven had a substantial proportion of participants with
respiratory disease. There was a small but signiﬁcant reduction in
hospital length of stay in participants who received the package of
care including early, low-intensity, exercise training (MD 1.08 days
shorter in the intervention group, 95% CI 1.93 to 0.22). Mobility
interventions that aim to facilitate discharge are considered to be
standard care for people hospitalised with AECOPD.
Early rehabilitation, which is a more intensive approach than
early mobilisation, may be applied during or after an AECOPD.
Early rehabilitation applies the well-established principles of
pulmonary rehabilitation to patients who are in the initial stages of
recovery from an AECOPD. This includes the use of moderate-to-
high intensity endurance training and/or strength training. Initial
studies suggested that this training approach is safe even in the
early stages of hospitalisation, with no signiﬁcant adverse events
and no increase in markers of systemic inﬂammation.51,52 A
Cochrane review including nine trials where rehabilitation was
commenced either during or after treatment for an AECOPD
showed a reduction in the odds of future hospital admission of 88%
(pooled OR 0.22, 95% CI 0.08 to 0.58) and a reduction in the odds of
death of 72% (OR 0.28, 95% CI 0.10 to 0.84).53 This systematic
review provided the ﬁrst robust evidence that early pulmonary
rehabilitation could impact on mortality, which was a signiﬁcant
advance in the ﬁeld and provided a strong rationale for its
implementation into physiotherapy practice.
Although the data supporting early rehabilitation presented in
the Cochrane review showed clear and consistent effects,53 a
recent trial suggests a more complex story. In a large trial (n = 389)
conducted in the UK, people hospitalised with AECOPD were
randomised to receive either very early rehabilitation (aerobic
training, strength training and neuromuscular electrical stimula-
tion), commencing within 48 hours of hospital admission, or usual
care, which included routine physiotherapy (airway clearance,
mobilisation and smoking cessation).54 The intervention was
applied for the duration of the hospital admission (median 5 days),
followed by an unsupervised home exercise program until week 6,
supported by telephone follow-up. There was no difference
between groups in the primary outcome of hospital readmission,
nor were there any clinically important differences in functional
outcomes. Importantly, there was also a surprising ﬁnding of an
increase in mortality for the early rehabilitation group at
12 months (25% in the early rehabilitation and 16% in usual care,
p = 0.03).
It is possible that the increase in mortality following early
rehabilitation occurred purely by chance. It is notable, however,
that uptake of outpatient pulmonary rehabilitation was signiﬁ-
cantly lower in the early rehabilitation group (14 vs 22% in usual
care group, p = 0.04), so it is possible that the intervention actually
received a lower overall ‘dose’ of rehabilitation than the usual care
group. Regardless, the strong design of this trial prompts us to
reassess the role and outcomes of early rehabilitation for COPD.On closer examination of the Cochrane review,53 it is apparent that
only three of the nine included trials tested a very early
rehabilitation intervention, commencing during the hospitalisa-
tion period.55–57 If meta-analysis is conducted separately for the
outcomes of the very early rehabilitation trials (deﬁned as those
commencing during hospitalisation for AECOPD), including the
recently published UK trial,54 there is a clear difference in
outcomes. Whilst rehabilitation started after hospital discharge
has a positive impact onmortality,58–60 the opposite is true for very
early rehabilitation started in the inpatient period (Figure 4; for a
more detailed forest plot, see Figure 5 on the eAddenda).54,55,57–60
The positive impact of early rehabilitation on hospital
readmission is no longer evident when trials of very early
rehabilitation are considered separately (Figure 6; for a more
detailed forest plot, see Figure 7 on the eAddenda).54,55,57–59,61,62
In the light of these new data, physiotherapists should
not prescribe a moderate or high intensity rehabilitation program
in the inpatient period during AECOPD. However, given the
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delivered following hospital discharge, all efforts should be made
to ensure that patients can access a pulmonary rehabilitation
program during this period.
Referral to outpatient pulmonary rehabilitation, commencing
after the acute admission is complete, should be routine practice
for patients who are discharged from hospital following treatment
of an AECOPD. However, recent studies have shown that the
positive outcomes of clinical trials may not be easy to replicate in
clinical practice. An audit conducted in the UK63 found that out of
448 patients admitted to hospital with an AECOPD, less than two-
thirds (n = 286) met the criteria for admission to an early
pulmonary rehabilitation program. The most common reasons
for exclusion were cognitive impairment or being unable to walk.
Less than one-third of eligible patients were referred to early
pulmonary rehabilitation (n = 90) and less than half of those
referred went on to complete the program (n = 43). This represents
less than 10% of all hospital discharges with AECOPD. Little
information is available to explain health professionals’ low rate of
referral of eligible patients and further work is required to
understand this failure of research translation. Patient-related
barriers have received more attention. People with COPD who
decline early pulmonary rehabilitation may experience feelings of
low self-worth, be reluctant to seek help, feel they are doing
enough exercise already and perceive pulmonary rehabilitation as
of limited value.64 These factors suggest that supportive and
ﬂexible referral pathways will be required to facilitate access and
uptake of early pulmonary rehabilitation for people recovering
from AECOPD.
Preventing exacerbations of COPD
Exacerbations of COPD have long-term consequences and high
costs for individuals, communities and the health system. Whilst
every exacerbation is important, a patient’s second exacerbation
that is severe enough to require hospitalisation may be a sentinel
event that marks an exponential increase in the rate of future
severe exacerbations and increased risk of mortality.65 This
suggests that there may be a window of opportunity after the
ﬁrst hospitalisation for AECOPD in which health professionals can
intervene to prevent or delay the second severe exacerbation and
modify the disease course. This is an important opportunity for
physiotherapists, who frequently have contact with patients
hospitalised for their ﬁrst AECOPD and be able to positively
inﬂuence future management.
Pharmacotherapy to prevent AECOPD
Vaccination and maintenance pharmacotherapy are the main-
stays of exacerbation prevention in people with COPD. In
community-dwelling older people, the inﬂuenza vaccine reduces
the risk of hospitalisation for pneumonia and inﬂuenza by 27%,with
anassociated48%reduction in the riskofdeath.66Thepneumococcal
vaccine is also commonly given, although there is less evidence for
its beneﬁts. Large randomised controlled trials have shown
convincing reductions in exacerbation risk and hospitalisation
using the combination of inhaled corticosteroids and long-acting
beta agonists67 or long-acting muscarinic antagonists.68 Current
treatment protocols indicate that either regimen can be used to
prevent exacerbations, or triple therapy can be given if necessary.1
Phosphodiesterase inhibitors have been shown to decrease exacer-
bations by 17% in moderate-to-severe COPD,69 although adverse
effects are more common than with inhaled medications.1
Non-pharmacotherapy to prevent AECOPDs
Pulmonary rehabilitation
Delivery of pulmonary rehabilitation after hospitalisation for
AECOPD reduces the odds of readmission for AECOPD by over 70%(Figure 6; for a more detailed forest plot, see Figure 7 on the
eAddenda).
Pulmonary rehabilitation, which must include whole body
exercise training, may provide opportunity to reverse the
deleterious effects of the AECOPD on skeletal muscle function
and physical activity. The non-exercise components of pulmonary
rehabilitation may also assist in preventing future exacerbations
by providing opportunities to optimise nutritional status; address
psychosocial issues such as anxiety and depression, which are
linked to exacerbation risk;70 encourage recognition and early
treatment of exacerbations; and enhance self-management skills.
Physiotherapists will need to identify and address individual
barriers to attendance to ensure program uptake and completion.
Self-management programs
People with COPD often live with ill health for many years and
must engage in complex health-related behaviours to ensure that
their disease is optimally managed. Self-management interven-
tions aim to encourage healthy behaviours and improve self-
management skills, including prevention and early treatment of
exacerbations. A meta-analysis including 1749 participants with
COPD from nine studies showed that self-management interven-
tions decreased the risk of respiratory-related hospitalisation by
over 40% (OR 0.57, 95% CI 0.43 to 0.75).71 However, a recent large
trial of self-management for COPD was stopped early due to
increased mortality in the intervention group,72 which has raised
concerns regarding the risks of strategies that require patients to
make independent choices regarding identiﬁcation and treatment
of AECOPD. However, when the body of evidence for self-
management programs is considered in its entirety, including
this trial,72 the meta-analysis shows no excess mortality risk.73
Nevertheless, this trial provides a reminder that behavioural
interventions may have a powerful impact on outcomes, and that
adequate support should be provided to ensure that patients can
successfully undertake the required behaviours.
Action plans
An action plan is an individualised, documented plan for
responding to increased respiratory symptoms. Action plans may
involve early commencement of pharmacotherapy and seeking
medical care. There is no evidence that use of an action plan alone
can decrease exacerbation rate or reduce healthcare utilisation,
although it may increase the initiation of antibiotic and
corticosteroid treatment at symptom onset.74 Action plans
accompanied by the support of a case manager may reduce
symptoms and accelerate symptom recovery after AECOPD.75 It is
likely that more intensive support is required for the potential
beneﬁts of action plans to be fully realised, such as that provided in
comprehensive self-management programs.
Other interventions
The impact of mucolytic therapy on rate of AECOPD is
inconsistent across trials76 and it is not currently recommended
for routine use.1 Whilst telemonitoring of symptoms and
physiological signals in community-dwelling people with COPD
had promising initial results,77 a recent large trial in the UK
showed no impact on hospitalisation for AECOPD.78 In this trial
both the telemonitoring and usual care groups had access to the
same high-quality and accessible clinical care, suggesting that
telemonitoring alone is not enough to improve outcomes.
Randomised trials have not shown an impact of long-term oxygen
therapy on exacerbation rate or hospitalisation, despite its
mortality beneﬁt.79,80 Smoking cessation is a cornerstone of
COPDmanagementwith a range of beneﬁts for patients, including
reduced exacerbation rate81 and reduced hospitalisation.82
Smoking cessation should therefore be encouraged and supported
in all people with COPD. Like all health professionals, phy-
siotherapists should take every opportunity to systematically
identify smokers, assess smoking status, offer smoking cessation
advice and refer for smoking cessation treatment.
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In recent years physiotherapy management for AECOPD has
increasingly focussed on exercise-based rehabilitation, both in
the outpatient and inpatient settings. In the light of recent
evidence,54 there is an urgent need for research that helps us to
understand the risks versus beneﬁts of very early rehabilitation
for AECOPD. Whilst studies in other populations such as critical
care and stroke indicates that very early rehabilitation has a
greater balance of beneﬁts than harms, this may not be applicable
to AECOPD. Future research should carefully investigate the
physiological effects of very early rehabilitation, including impact
on inﬂammatory status, and rigorously document the total dose of
rehabilitation achieved over the course of the trial. Usual care
should be deﬁned in detail. A well-powered study conducted
across multiple settings will be required, and a safety monitoring
board will be mandatory.
Although physiotherapists commonly use breathing strategies
to manage symptoms and enhance exercise tolerance during
AECOPD, the evidence underpinning this practice is not convinc-
ing. As hospital admissions for AECOPD become shorter and the
emphasis on achieving readiness for discharge becomes larger,
there is a need to demonstrate that breathing techniques
contribute to both patient wellbeing and improved function.
Future research should examine whether breathing exercises give
rise to clinically meaningful and measurable beneﬁts for patients
hospitalised with AECOPD; these include improved functional
exercise tolerance, a faster return to independence and improved
disease mastery. Similarly, any future trials of airway clearance
techniques for AECOPD should select clinically meaningful out-
comes and include only those phenotypes considered most likely
to beneﬁt (eg, those who are productive of sputum). Multi-centre
trials will be required if future studies are to provide deﬁnitive
answers regarding the role of these physiotherapy techniques
during AECOPD.
Many physiotherapy interventions for AECOPD aim to restore
or maintain function, such that patients can achieve a safe
discharge and return to an active lifestyle in the community.
However, measuring the success of physiotherapy interventions
for AECOPD is challenging. Patients may be severely dyspnoeic and
unable to tolerate assessments that are commonly used in an
outpatient setting, such as the 6-minute walk test. Dedicated
testing spacemay not be available in a hospital ward environment.
Length of hospital stay is often only a few days and assessment
tools must therefore be responsive to changes occurring over a
short period. Recently several simple tests of functional capacity
have been examined in COPD and may prove useful in this setting.
These include the 4-metre gait speed test,83 a number of variants
on sit-to-stand tests,84,85 and the Timed-Up-and-Go test.86 These
tests are reliable, valid and responsive in stable COPD; however,
their utility in AECOPD has not yet been examined. Whilst these
tests may prove to be useful as global measures of function during
and after an AECOPD, they provide little information about the
impact of exercise on physiological parameters and will not be
useful for exercise prescription. Further research is needed to
identify an optimal assessment tool for physiotherapy interven-
tions in the setting of AECOPD.
In the clinical setting, physiotherapists have a strong and
growing body of evidence to guide their practice when treating
people with AECOPD (Figure 1). The evidence for important
beneﬁts of pulmonary rehabilitation after AECOPD is strong;
referral to pulmonary rehabilitation at hospital discharge should
be a priority for physiotherapy care. A clinical challenge that must
be addressed is the articulation of inpatient physiotherapy
management with outpatient pulmonary rehabilitation programs.
Given the compelling beneﬁts of rehabilitation after AECOPD for
patients and the healthcare system, and the abysmal uptake of this
treatment,63 more efforts must be made to provide ﬂexible and
supportive pathways into pulmonary rehabilitation followinghospital discharge. For patients whose attendance at an outpatient
program is precluded by dyspnoea or frailty, this may require
consideration of alternative rehabilitation models, such as well-
resourced home-based programs.87 Finally, physiotherapists
should take a more active role in prevention of future AECOPD.
Using evidence-based treatments such as rehabilitation and self-
management training, physiotherapists have the tools to make a
long-term impact on the health, wellbeing and longevity of people
with COPD.
eAddenda: Figures 3, 5 and 7 can be found online at
doi:10.1016/j.jphys.2014.08.018
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